Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer's Dementia: Findings in Two Cohorts.

Lue LF, Sabbagh MN, Chiu MJ, Jing N, Snyder NL, Schmitz C, Guerra A, Belden CM, Chen TF, Yang CC, Yang SY, Walker DG, Chen K, Reiman EM.

Front Aging Neurosci. 2017 Jul 24;9:226. doi: 10.3389/fnagi.2017.00226. eCollection 2017.

2.

Protein/Peptide Aggregation and Amyloidosis on Biointerfaces.

Lu Q, Tang Q, Xiong Y, Qing G, Sun T.

Materials (Basel). 2016 Aug 30;9(9). pii: E740. doi: 10.3390/ma9090740. Review.

3.

Plasma biomarkers are associated with agitation and regional brain atrophy in Alzheimer's disease.

Hsu JL, Lee WJ, Liao YC, Lirng JF, Wang SJ, Fuh JL.

Sci Rep. 2017 Jul 11;7(1):5035. doi: 10.1038/s41598-017-05390-1.

4.
5.

Soluble oligomeric amyloid-β induces calcium dyshomeostasis that precedes synapse loss in the living mouse brain.

Arbel-Ornath M, Hudry E, Boivin JR, Hashimoto T, Takeda S, Kuchibhotla KV, Hou S, Lattarulo CR, Belcher AM, Shakerdge N, Trujillo PB, Muzikansky A, Betensky RA, Hyman BT, Bacskai BJ.

Mol Neurodegener. 2017 Mar 21;12(1):27. doi: 10.1186/s13024-017-0169-9.

6.

The effects of different familial Alzheimer's disease mutations on APP processing in vivo.

Thordardottir S, Kinhult Ståhlbom A, Almkvist O, Thonberg H, Eriksdotter M, Zetterberg H, Blennow K, Graff C.

Alzheimers Res Ther. 2017 Feb 16;9(1):9. doi: 10.1186/s13195-017-0234-1.

7.

Amyloid beta peptide 22-35 induces a negative inotropic effect on isolated rat hearts.

Yousefirad N, Kaygısız Z, Aydın Y.

Int J Physiol Pathophysiol Pharmacol. 2016 Dec 25;8(4):146-151. eCollection 2016.

8.

A digital enzyme-linked immunosorbent assay for ultrasensitive measurement of amyloid-β 1-42 peptide in human plasma with utility for studies of Alzheimer's disease therapeutics.

Song L, Lachno DR, Hanlon D, Shepro A, Jeromin A, Gemani D, Talbot JA, Racke MM, Dage JL, Dean RA.

Alzheimers Res Ther. 2016 Dec 15;8(1):58.

9.

Identifying biomarkers of dementia prevalent among amnestic mild cognitively impaired ethnic female patients.

Grewal R, Haghighi M, Huang S, Smith AG, Cao C, Lin X, Lee DC, Teten N, Hill AM, Selenica MB.

Alzheimers Res Ther. 2016 Oct 18;8(1):43.

10.

Biomarkers for the Early Detection and Progression of Alzheimer's Disease.

Counts SE, Ikonomovic MD, Mercado N, Vega IE, Mufson EJ.

Neurotherapeutics. 2017 Jan;14(1):35-53. doi: 10.1007/s13311-016-0481-z. Review.

PMID:
27738903
11.

Prospective longitudinal course of cognition in older subjects with mild parkinsonian signs.

Lerche S, Brockmann K, Pilotto A, Wurster I, Sünkel U, Hobert MA, von Thaler AK, Schulte C, Stoops E, Vanderstichele H, Herbst V, Brix B, Eschweiler GW, Metzger FG, Maetzler W, Berg D.

Alzheimers Res Ther. 2016 Oct 10;8(1):42.

12.

Quantitative analysis of co-oligomer formation by amyloid-beta peptide isoforms.

Iljina M, Garcia GA, Dear AJ, Flint J, Narayan P, Michaels TC, Dobson CM, Frenkel D, Knowles TP, Klenerman D.

Sci Rep. 2016 Jun 27;6:28658. doi: 10.1038/srep28658.

13.

Non-invasive screening for early Alzheimer's disease diagnosis by a sensitively immunomagnetic biosensor.

Li SS, Lin CW, Wei KC, Huang CY, Hsu PH, Liu HL, Lu YJ, Lin SC, Yang HW, Ma CC.

Sci Rep. 2016 Apr 26;6:25155. doi: 10.1038/srep25155.

14.

Amyloid-β and Astrocytes Interplay in Amyloid-β Related Disorders.

Batarseh YS, Duong QV, Mousa YM, Al Rihani SB, Elfakhri K, Kaddoumi A.

Int J Mol Sci. 2016 Mar 4;17(3):338. doi: 10.3390/ijms17030338. Review.

15.

Amyloid Hypothesis: Is There a Role for Antiamyloid Treatment in Late-Life Depression?

Mahgoub N, Alexopoulos GS.

Am J Geriatr Psychiatry. 2016 Mar;24(3):239-47. doi: 10.1016/j.jagp.2015.12.003. Epub 2016 Jan 14. Review.

16.

Age-dependent inverse correlations in CSF and plasma amyloid-β(1-42) concentrations prior to amyloid plaque deposition in the brain of 3xTg-AD mice.

Cho SM, Lee S, Yang SH, Kim HY, Lee MJ, Kim HV, Kim J, Baek S, Yun J, Kim D, Kim YK, Cho Y, Woo J, Kim TS, Kim Y.

Sci Rep. 2016 Feb 2;6:20185. doi: 10.1038/srep20185.

17.

Cerebrospinal Fluid Aβ40 Improves the Interpretation of Aβ42 Concentration for Diagnosing Alzheimer's Disease.

Dorey A, Perret-Liaudet A, Tholance Y, Fourier A, Quadrio I.

Front Neurol. 2015 Nov 27;6:247. doi: 10.3389/fneur.2015.00247. eCollection 2015.

18.

Cognitive Function, Progression of Age-related Behavioral Changes, Biomarkers, and Survival in Dogs More Than 8 Years Old.

Schütt T, Toft N, Berendt M.

J Vet Intern Med. 2015 Nov-Dec;29(6):1569-77. doi: 10.1111/jvim.13633. Epub 2015 Oct 13.

19.

The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans.

Kang JH, Korecka M, Figurski MJ, Toledo JB, Blennow K, Zetterberg H, Waligorska T, Brylska M, Fields L, Shah N, Soares H, Dean RA, Vanderstichele H, Petersen RC, Aisen PS, Saykin AJ, Weiner MW, Trojanowski JQ, Shaw LM; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2015 Jul;11(7):772-91. doi: 10.1016/j.jalz.2015.05.003. Review.

20.

Revisiting the dilution factor as vital parameter for sensitivity of ELISA assay in CSF and Plasma.

Thakur K, Sharma S, Prabhakar S, Gupta P, Anand A.

Ann Neurosci. 2015 Jan;22(1):37-42. doi: 10.5214/ans.0972.7531.220108.

Supplemental Content

Support Center